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Abstract
Introduction. Blood transfusion is a lifesaving procedure for patients affected by hema-
tological diseases or hemorrhage risk. 
Aim. This retrospective study was aimed to evaluate clinical safety of pediatric transfu-
sions by comparing the frequency of adverse events caused by apheretic blood compo-
nents vs whole blood. 
Methods. From 2011 to 2015, 214 patients (blood malignancy patients, n = 144 and 
thalassemic patients, n = 70) received 12 531 units of blood components. The adverse 
acute reactions occurred during patient hospitalization were reported to the Hemovigi-
lance system and assessed by fitting a logistic mixed-effect model. 
Results. A total of 33 (0.3%) adverse acute events occurred. Odds ratio (OR) of adverse 
events from apheresis vs whole blood transfusion adjusted by patient classification was 
not statistically significant (OR [95% CI], 0.75 [0.23-2.47]). 
Conclusion. Our findings showed no significant differences in the prevalence of adverse 
acute events between blood component collected by apheresis vs whole blood in our 
study center. 
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Blood transfusion is a lifesaving therapy for patients 
affected by anemia, coagulation disorders, bone mar-
row aplasia, as well as many other conditions compro-
mising oxygen transport and hemostatic function [1-3]. 
Despite the increasing of transfusion safety achieved 
by both application of good manufacturing practice 
(GMP) and appropriate therapeutic protocols, blood 
components can be associated with acute (< 24 h) or 
delayed (≥ 24 h) adverse effects, especially in transfu-
sion-dependent pediatric patients [2].
Acute or delayed adverse effects are classified as im-
munological and non immunological reactions. Acute 
adverse events include hemolytic, febrile non hemo-
lytic, allergic and anaphylactic reactions, as well as lung 
injury, infection or sepsis, and circulatory overload. De-
layed adverse events include erythrocyte and platelet al-
loimmunization, hemolytic reactions, post-transfusion 
purpura, immunomodulation, graft versus host disease, 
as well as iron overload in long-term transfusion [4, 5]. 
When acute reactions occur, it is necessary to stop the 
transfusion procedure to establish an appropriate treat-
ment. Besides, the event must be notify to Blood Bank 
[4, 5]. Laboratory parameters include hemoglobinemia 
(pink or red serum/plasma), hemoglobinuria, positive 
direct anti-globulin test (DAT), elevated indirect and 
direct bilirubin test, and red blood cell (RBC) abnor-
malities, such as schistocytes in intravascular hemolysis 
or spherocytes in extravascular hemolysis [4, 5]. 
According to the Italian Report of Haemovigilance 
(2016), from January 1st to December 31st 2016, 1958 
adverse reactions were notified in recipients of allo-
geneic blood components (one every 1560 transfused 
units); taking into account only adverse reactions that 
are probably or certainly imputable with a high level of 
severity the frequency is one every 339 543 transfused 
units. It is estimated a more than double incidence of 
transfusion-related adverse acute events in pediatric 
than adult patients (538 vs 252 per 100 000 transfu-
sions) showing a higher frequency of allergic, febrile 
non hemolytic, and hypotensive reactions [1, 6]. The 
most frequent side effects in pediatric population are 
of acute type, including both mild allergic reactions 
(urticarial, cutaneous) and mild respiratory symptoms 
[6, 7]. In 2016, the most frequently notified reactions 
were febrile non-haemolytic reactions (39.2%) and al-
lergic manifestations with only mucosal and cutaneous 
symptoms (29%), representing about 68.2% of all no-
tified adverse reactions in recipients [8]. In particular, 
these adverse acute events are mainly associated with 
platelet (PLT) transfusions followed by RBC and plas-
ma transfusions [6, 7]. The morbidity of blood compo-
nents requires extreme concern in transfusion practice 
based on the clinical profiles. Greater efforts should be 
aimed to administer the lowest dose of blood compo-
nents, thus avoiding both unnecessary multiple donor 
exposures and prophylactic transfusions. Moreover, cli-
nicians should evaluate every therapeutic opportunity 
to reduce blood transfusion-related risk, such as infec-
tion and allo-immunization [6, 10]. In this context, pa-
tient blood management (PBM) programs are designed 
to reduce the use of transfusions also through intraop-
erative, preoperative postoperative strategies aimed at 
limiting the use of allogeneic components. The PBM 
programs are well established and implemented in the 
adult environment and it should be necessary pediatric 
PBM goal directed protocols even more restrictive than 
those for adults [9].
Nowadays, infection is still a critical issue because 
current screening methods are not still able to cover 
the window period and discriminate the plethora of 
emerging pathogens [10, 11]. The screening of blood 
donors using well standardized and highly sensitive 
laboratory assays has significantly increased the safety 
of blood transfusion [10]. Indeed, in developed coun-
tries, the current risk is very low for a number of known 
viruses (e.g. HIV, HBV, HCV) which can be detected 
accurately in the donor blood and lower than the risk 
related to non-infectious acute blood transfusion reac-
tions (e.g. TACO, TRALI, etc.) [10]. However, emerg-
ing pathogens could represent a risk for recipients, 
including hepatitis E virus (HEV) that is increasing in 
European countries with a significant variability among 
the different geographical areas [10]. In this regard, it 
could be useful the application of new pathogen reduc-
tion technologies (PRTs) to improve clinical patient 
outcome; however, there are some limitations: 1) PRTs 
are not available for all blood components; 2) current 
commercial PRTs are not equally effective on all the 
pathogens; 3) some detrimental alterations have been 
found in PRTs treated blood components [12]. Besides, 
efficacy, type and cost of side effects, as well as sani-
tary policy should be better analyzed, thus allowing the 
Blood Bank to set up all the possible strategies aimed to 
improve the transfusion medicine safety, particularly in 
pediatric population [9, 13-16]. Transfusion reactions 
in pediatric populations have not been well explored; 
however, a study evaluating 126 pediatric patients re-
ported a percentage of 14.4% of acute transfusion re-
action to PLT transfusion [8]. Generally, donation by 
apheresis procedures are correlated with fewer adverse 
events [16].
In light of this, we report our single-center experience 
focused on a retrospective analyses aimed to evaluate 
putative difference between apheresis and whole blood 




From 2011 to 2015, blood components, collected at 
the Division of Clinical Immunology, Immunohema-
tology and Transfusion Medicine, were transfused in 
patients with blood malignancy or thalassemia in the 
Pediatric Department, at Università degli Studi della 
Campania “Luigi Vanvitelli”, Naples, Italy. Pediatric 
patients (n = 214, aged from 8 to 19 years) received 
randomized blood components obtained by apheresis 
or by whole blood, according to the availability in the 
Blood Bank. Exclusion criteria were the presence of 
pre-existing cardiopulmonary affections and medi-
cal history of allergy and anaphylaxis. Detailed forms 
on the type and rate of transfusion related to adverse 
events occurred during hospitalization were obtained 
























from Pediatric Division and sent mandatorily to our 
Division for the Hemovigilance Network. The number 
and the type of blood components transfused under 
normal clinical practice were obtained from our elec-
tronic database. A transfusion reaction was an adverse 
acute event attributable to a blood product infusion 
(PLTs, RBCs, plasma). Data on all adverse acute events 
were registered using authorized and approved pro-
cedures. Guidelines on assessing donor suitability for 
blood donation are reported on DM November 2, 2015 
by Italian Minister of Health (www.gazzettaufficiale.it/
eli/id/2015/12/28/15A09709/sg) and according to the 
Society of Transfusion Medicine and Immunohematol-
ogy (www.centronazionalesangue.it/sites/default/files/
it_standards_transf_med.pdf) [17]. Donors were de-
ferred in presence of risk behavior, cardiac pathologies, 
autoimmune and neoplastic diseases and the use of par-
ticular drugs according to Italian legislation. 
Blood derivates
Blood donation was performed by apheresis or by 
whole blood. During the apheresis procedure, the donor 
is connected through a single venous access to a sterile 
disposable kit in a closed circuit. The apheresis allowed 
the collection of aliquots of RBCs, PLTs and plasma us-
ing Haemonetics MCS+ 9000 system blood cell separa-
tor (Haemonetics S.A. Signy Centre, Ruedes Flèchères 
6, Svizzera). The main advantage of this procedure is 
the low extracorporeal volume (calculated by volume of 
the apheresis chamber, the hematocrit (Hct) and total 
blood volume of the donor), which avoids modifications 
in donor pressure. Through the centrifugal force, blood 
cell separators collect blood aliquots during the discon-
tinuous flow procedure throughout the programs for the 
multicomponent collections of RBCs (erytro-apheresis, 
EA, 947F) and RBCs-plasma (erythro-plasmapheresis, 
EPA, 947F) and PLTs-plasma (platelet-plasmapheresis, 
PLT-A, 994EF) while the remaining part is returned 
to the donor. The circuit used is sterile and disposable 
while donor extracorporeal part is anticoagulated by us-
ing a citrate solution. For EPA/EA, RBCs target yields 
were programmed to 230-280 g of absolute RBCs (leu-
kodepleted) and 450 mL of plasma. After collection, 70-
80 g saline-adenine-glucose-mannitol preservative solu-
tion was automatically added to RBCs and the filtration 
was performed routinely after the last return cycle by 
gravity through the integrated filters for leukodeple-
tion. RBCs were stored at 4 °C for 42 days. For PLT-A, 
platelet target yields were programmed to range 2.5-3.5 
× 1011 of PLTs and 450 mL of plasma. After collection, 
PLTs were re-suspended in 130-150 mL of SSP solu-
tion (Macopharma, Italy) and automatically filtrated 
according to the current legislation for leukodepletion. 
PLTs were stored at room temperature on continuous 
shaker for up to 5 days [18-21]. By apheresis, 400-650 
mL of plasma was collected (DM November 2, 2015 
by Italian Minister of Health (www.gazzettaufficiale.it/
eli/id/2015/12/28/15A09709/sg) and according to the 
Society of Transfusion Medicine and Immunohematol-
ogy (www.centronazionalesangue.it/sites/default/files/
it_standards_transf_med.pdf) [17].
Blood bags were handled to avoid any bacterial con-
tamination in the blood product collected. Blood prod-
ucts (PLTs and RBCs) were subjected to periodic and 
randomized checks for microcontaminations [11, 17]. 
Whole blood was processed within 8 hours after dona-
tion to obtained platelet concentrates (PC), fresh fro-
zen plasma (FFP), packed RBCs (EC), and leukode-
pleted RBCs (EL) by using a closed system collected in 
citrate-phosphate-double dextrose. RBC target yields 
were programmed equal to be at least 280 mL of leu-
kodepleted RBCs with a Hct level of 0.50-0.70% and 
plasma is collected with a volume ranging from 400 mL 
to 730 mL.
Statistical analysis 
Continuous variables were reported as either mean 
and standard deviation (SD) or median and interquar-
tile range (IQRs) according to their distribution, as as-
sessed by the Shapiro-Wilk test and compared with t-test 
or Wilcoxon-Mann-Whitney test. Categorical variables 
were reported as absolute numbers and percentages 
and compared with Pearson’s chi-square test or Fish-
er’s exact test as indicated. Rate of adverse events were 
calculated as number of events divided by number of 
transfusion and compared between transfusion proce-
dures. The effect of transfusion procedures on adverse 
event was assessed by fitting a logistic mixed-effects 
model [22]. An unstructured within-subject covariance 
matrix was used in the analysis (i.e. variances and cova-
riance were allowed to vary at each observation point). 
Transfusion procedures according to the classification 
of patients (blood malignancies and thalassemic pediat-
ric patients) were first tested; if the interaction was sta-
tistically significant at 0.05 level (i.e., there was enough 
evidence that adverse event varied among transfusion 
procedures), a separate model was performed sepa-
rately for blood malignancies and thalassemic pediatric 
patients. All analyses were replicated for patients with 
both transfusion procedures. 
RESULTS
In our single-center experience, 12 531 randomized 
blood components (n = 2662 blood malignancy and n = 
9869 thalassemic patients) were transfused to 214 pa-
tients (n = 144 blood malignancy and n = 70 thalasse-
mic patients). As shown in Table 1, the two populations 
(blood malignancy and thalassemic patients) showed 
different characteristics and were considered separate-
ly. Age, gender, number of transfusion, time of observa-
tion, and different blood components transfused were 
reported in Table 1. Male gender was 60% and 46% in 
blood malignancies and thalassemic patients, respec-
tively. Mean age was 8.5±5.3 years in blood malignancy 
and 19.4±12.8 years in thalassemic patients. Median 
time of observation was 0.50 years (interquartile range 
(IQR) 0.11-0.83) in blood malignancy patients and 4.9 
years (IQR 3.2-4.9) in thalassemic patients. 
Adverse acute event rates for total and single transfu-
sion are reported in Table 2. A total of 33/12 531 (0.3%) 
adverse acute events occurred. Only the adverse reac-
tions observed during hospitalization were reported in 
our study. They included only mild acute reactions. In 
particular, 4 for EA (3 minor allergic reactions, and 1 
























episode of bronchospasm); 4 for EL (2 minor allergic 
reactions, 1 febrile episode, and 1 episode of vomit-
ing); and 6 for EC (3 minor allergic reactions, 1 febrile 
episode, and 2 episodes of vomiting). Regarding PTL 
transfusion, we registered 19 adverse acute events for 
PC (9 minor allergic reactions, 2 febrile episodes, 1 epi-
sode of vomiting, and 7 episodes of bronchospasm). No 
adverse acute events for PLT-A, FFP, and plasma apher-
esis were reported (P = NS). No significant difference 
in rate of adverse acute events between blood compo-
nents obtained by apheresis or whole blood was ob-
served. Data have been confirmed by considering also 
patients who received both types of blood components 
(n = 78 blood malignancies patients and n = 66 thalas-
semic patients for a total n = 144 pediatric patients). 
The interaction term between blood products  and the 
classification of patients was not statistically significant 
(p = 0.13). Then, a single logistic mixed-effect model 
was performed (Table 3). No difference was found in 
the distribution of adverse events between blood com-
ponent collected by apheresis vs whole blood (Table 
3). Odds ratio (OR) of adverse events in blood com-
ponents collected by apheresis vs whole blood adjusted 
by patient classification was not statistically significant 
(OR [95% CI], 0.75 [0.23-2.47]). Data were confirmed 
for patients who received both blood components (OR 
[95% CI], 0.68 [0.20-2.38]).
DISCUSSION
Adverse events in transfusion medicine are largely de-
termined by the clinical conditions and the patient state 
of immune reactivity, in which the choice of the trans-
fused product can be useful in limiting subsequent ad-
verse reactions. Whereas the blood components collect-
ed both by AF and by SI are valid in the same way, the 
availability of both allows us to allocate the best product 
to a certain type of patient, reducing adverse events in a 
personalized dimension. Pediatric patients are more vul-
nerable than adults showing a higher frequency of trans-
fusion related side effects [7]. To our knowledge, this is 
Table 1 







Male gender n (%) 87 (60.4) 32 (45.7) 0.04
Age mean (sd) 8.5 (5.3) 19.4 (12.8) <0.001
Number of transfusion median (IQR range) 10.5 (4-25.3) 157 (63.5-209.2) <0.001
Period of observation, years (median (IQR range) 0.50 (0.11-0.83) 4.9 (3.2-4.9) <0.001
Type of blood components n (%)
Packed Red Blood Cells without Buffy Coat  (EC) 88 (61.1) 59 (84.3) <0.001
Leukodepleted Red Blood Cells (EL) 84 (58.3) 66 (94.3) <0.001
Erithro-Apheresis (EA) 2 (1.4) 20 (28.6) <0.001*
Erithro-Plasma-Apheresis (EPA) 65 (45.1) 66 (94.3) <0.001
Platelet Concentrates (PC) 45 (31.3) 2 (2.9) <0.001*
Pool Platelet from Buffy Coat (Pool-PLT) 50 (34.7) 0 (0.0) <0.001*
Platelet Apheresis (PLT-A) 45 (31.3) 0 (0.0) <0.001*
Plasma Fresh Frozen (FFP) 16 (11.1) 1 (1.4) 0.01*
Plasma from Erithro-Plasma-Apheresis (P-EPA) 8 (5.6) 1 (1.4) 0.28*
Plasma from Platelet-Plasma-Apheresis (P-PPA) 3 (2.1) 1 (1.4) 0.99*
*Fisher’s exact test
Table 2 
Distribution of adverse events by each transfusion in patients subgroups
Total Apheresis Whole blood p-value
Only blood malignancy patients (n = 144) 15/2662 (0.56%) 1/333  
(0.30%)
14/2329 (0.60%) 0.493
Only thalassemic patients (n = 70) 18/9869 (0.18%) 3/1208 
(0.25%)
15/8661 (0.17%) 0.566
Blood malignancy patients with both 
transfusion procedures
(n = 78) 11/2248 (0.49%) 0/330 (0.0%) 1/1918 (0.57%) 0.168
Thalassemic patients with both transfusion 
procedures
(n = 66) 17/9860 (0.17%) 3/1208 
(0.25%)
14/8652 (0.16%) 0.497
Data are reported as number of events/number of transfusion (percentage).
























the first study investigating a putative different rate of 
collateral effects between apheresis and whole blood col-
lection in pediatric patients. By results, no difference in 
adverse acute events occurred from blood components 
(RBCs, PLTs, plasma) obtained by apheresis or by whole 
blood in blood malignancy and thalassemic pediatric pa-
tients. Interestingly, adverse acute reactions observed (n 
= 33) were mild and did not cause further hospitalization. 
This may be related to the benefits of the increased use 
of leukodepleted whole blood components characterized 
by helpful pre-storage and bedside filters, as required by 
Italian legislation [17]. Since it is well known that cy-
tokines released from residual leukocytes contaminating 
blood components are actively involved in a number of 
blood transfusion complications, most authors recom-
mended the leukodepletion, especially for selected cat-
egories of patients, such as recipients of “long-term” 
transfusion regimens [23]. Leukodepleted RBCs and 
PLTs produced both from whole blood and apheresis 
reduced the risk of HLA immunization in recipients, as 
well as transmission of new variant Creutzfeldt-Jakob or 
cytomegalovirus avoiding febrile reactions [24]. The in-
troduction of apheresis changed the final blood products 
with modification of storage solution and a lower vol-
umes of residual plasma, thus producing RBCs with con-
trolled volumes and increased Hct value [25]. In addi-
tion, apheresis provided PLTs with 4 fold lower exposure 
to donor antigens as compared to a single pool of PCs 
(with a consequent lower risk of infection, development 
of alloimmunity, refractoriness, and transfusion-related 
acute lung injury in recipients). 
Consistently to our data, a recent preliminary report 
indicated that PLT transfusion reactions did not occur 
more often in recipients transfused with apheresis vs 
buffy coat platelet concentrates [25]. Although apher-
esis RBCs present a citrate concentration 2.5-3.0-fold 
higher than standard RBCs (5.72±3.01 vs 1.88±0.31), 
no adverse acute events correlated to lower plasma cal-
cium (muscle tremor, paresthesia, cardiac arrhythmia) 
caused by citrate toxicity were registered [25].
CONCLUSIONS
Globally, our study data confirm a low incidence of 
pediatric transfusion reactions (0.33%). Regarding the 
RBCs, our data showed that the pre-filtered RBCs col-
lected with the AF are absolutely superimposable to 
those collected from SI. Indeed, the new systems of 
decomposition of the whole blood allow a separation 
of all the components of the blood in an automatic way 
reducing the risk of leaving a part of plasma adhered to 
the red cells. Consequently the use of apheresis for red 
blood donors, in most CTs only concerns rare pheno-
types in which it is possible to collect a double unit of 
red blood cells tailored on donor Hb. However hema-
tocrit of our whole red blood sacs is around 60% while 
apheresis has 70% and, obviously, this must be evalu-
ated in clinical practice as it should affect transfusion 
intervals. As regards platelets, apheresis have shown 
a greater transfusion safety and they are preferred in 
our Center through a massive and constant policy of 
increasing donations. 
However, our single-center experience presents many 
limitations due to the heterogeneity of population ex-
amined, to the possible underestimation of symptoms, 
due to the inability of children to report correctly path-
ological signs, as well as the lack of data in the popula-
tion from 0 to 8 years and the patient condition of im-
munosuppression. In addition, reported  adverse events 
included only reactions occurred when patients was 
under medical supervision. Transfusion reactions after 
hospital discharge was not monitored. Despite the low 
reported adverse events in pediatric patients, we cannot 
exclude the infectious risk of non-removible blood com-
ponents even with the latest methods of analysis. These 
considerations according with the latest directives and 
strategies of the PBM impose an ever lower recourse 
to allogeneic blood components and a greater use of 
alternative anesthetic, pharmacological and  surgical 
strategies to blood transfusion. Particularly, in  pediatric 
patients we advocate large-scale planning and applica-
tion of restrictive PBMs models.
In our opinion, a randomized study involving a larger 
number of patients should be performed to suggest ad-
ditional strategies to establish more accurate criteria to 
prevent adverse acute reactions in transfusion-depen-
dent pediatric patients.
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Table 3 
Statistical significance of transfusion adverse events: logistic mixed-effect model
All pediatric patients Patients 
Apheresis and whole blood
Odds Ratio of adverse
events (95% CI)
p-value Odds Ratio of adverse
events (95% CI)
p-value
Apheresis vs whole blood 0.75 (0.23-2.47) 0.634 0.68 (0.20-2.38) 0.551
Thalassemic vs blood malignancy patients 0.30 (0.04-2.10) 0.223 0.34 (0.05-2.15) 0.252
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